Treatment for Oral Lichen Planus using Paeoniflorin and Light Therapy
Clinical Study of Combined Treatment of Oral Lichen Planus With Paeoniflorin and Photodynamic Therapy
This study is testing a new treatment for Oral Lichen Planus using a natural compound from Chinese medicine and light therapy to see if it helps relieve symptoms and improve patients' health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 156 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05973097 on ClinicalTrials.gov |
What this trial studies
This project aims to treat Oral Lichen Planus (OLP), a chronic inflammatory condition of the oral mucosa, using a combination of paeoniflorin, a compound from traditional Chinese medicine, and photodynamic therapy. The study will categorize patients based on TCM differentiation and conduct a randomized controlled trial to evaluate the effectiveness of this combined treatment approach. By targeting the underlying autoimmune mechanisms and utilizing innovative therapies, the study seeks to improve patient outcomes and enhance understanding of treatment mechanisms for OLP.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with Oral Lichen Planus.
Not a fit: Patients who are pregnant, lactating, or have serious systemic diseases or tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a more effective management option for patients suffering from Oral Lichen Planus.
How similar studies have performed: While the combination of these therapies is innovative, individual treatments have shown efficacy in previous studies, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with oral lichen planus * male or female patients older than 18 years of age * patients willing to participate with signed informed consent. Exclusion Criteria: * pregnant or lactating * had serious systemic diseases of the heart, lung, liver, and kidney, or had tumors * were unwilling to participate in the experiment.
Where this trial is running
Beijing
- Peking University Third Hospital — Beijing, China (Recruiting)
Study contacts
- Principal investigator: Zhihui Zhang — Peking University Third Hospital
- Study coordinator: Zhihui Zhang, Dr.
- Email: wisdomzhangzhihui@163.com
- Phone: 010-82266125
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.